WEI WANG: Open Payments
NPI 1497330849 · PEORIA, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,744 in 99 payments from 43 companies in 2025. Trend: 2023 $1,599 · 2024 $3,240 · 2025 $2,744
Food & beverage: $2,412Long term medical supply or device loan: $283Education: $50
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 10 | $425 |
| AstraZeneca Pharmaceuticals LP | 7 | $293 |
| Merck Sharp & Dohme LLC | 8 | $243 |
| ABBVIE INC. | 8 | $185 |
| Pharmacosmos Therapeutics Inc. | 1 | $145 |
| Janssen Biotech, Inc. | 7 | $138 |
| Celgene Corporation | 5 | $101 |
| Gilead Sciences, Inc. | 4 | $89 |
| Incyte Corporation | 2 | $70 |
| GENZYME CORPORATION | 2 | $61 |
Products named: KISQALI, KEYTRUDA, MONOFERRIC, DATROWAY, Trodelvy, REBLOZYL, DARZALEX, LUPRON DEPOT.
Industry payments across AZ — which companies pay providers there.
